Multiple Myeloma: all 3,712 studies

Page 8 of 38. Open to participants first (752), then studies with results posted, then the rest; newest registration first within each.

• Study to Evaluate CCS1477 (Inobrodib) in Haematological MalignanciesRecruitingNCT04068597Phase 1/2
• Comparation of Chidamide Plus VRD (Bortezomib, Lenalidomide, Dexamethasone) With VRD Regimen for Primary High-Risk Multiple Myeloma PatientsRecruitingNCT04025450Phase 1/2
• Fluciclovine PET/CT in Multiple Myeloma PatientsRecruitingNCT03966443
• Carfilzomib Based Chemotherapy Mobilization for Autologous Stem Cell Transplants in Multiple MyelomaRecruitingNCT03909412Phase 1
• Low-Dose Radiotherapy in Treating Painful Bone Metastases in Patients With Multiple MyelomaRecruitingNCT03858205Not applicable
• Allogeneic Hematopoietic Cell Transplantation From HLA-matched Donor After Flu-Mel-PTCy Versus Flu-Mel-ATG Reduced-intensity ConditioningRecruitingNCT03852407Phase 2
• Evaluation of PET 18F-Fludarabine for the Initial Assessment and End-treatment of Symptomatic Multiple Myeloma PatientsRecruitingNCT03832127Phase 1
• Post-Op Pain Control for Prophylactic Intramedullary Nailing.RecruitingNCT03823534Phase 3
• A Nationwide Phase 2 Trial of Patients With Smoldering and Active Multiple Myeloma (MM)Enrolling by invitationNCT03815279Phase 2
• MYeloma Resistance And Clonal EvolutionRecruitingNCT03807128
• Managed Access Program for Combination Treatment With Belantamab Mafodotin in Multiple MyelomaAvailableNCT03763370
• Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple MyelomaRecruitingNCT03761108Phase 1/2
• CURATE.AI Optimized Modulation for Multiple MyelomaRecruitingNCT03759093Phase 2/3
• Registry for Adults With Plasma Cell Disorders (PCD's)RecruitingNCT03717844
• Cardiovascular Prevention Strategies in Elderly Patients With Cancer (CARTIER Clinical Trial)RecruitingNCT03711110Not applicable
• Predicting Progression of Developing Myeloma in a High-Risk Screened Population (PROMISE)Enrolling by invitationNCT03689595
• VRD as Induction Followed by VR Maintenance in Patients With Newly Diagnosed High Risk Multiple MyelomaRecruitingNCT03641456Phase 2
• Long-term Follow-up of Patients Treated With Genetically Modified Autologous T CellsEnrolling by invitationNCT03628612Phase 2
• The Indiana Myeloma RegistryRecruitingNCT03616483
• The Role of Ixazomib in Autologous Stem Cell Transplant in Relapsed Myeloma - Myeloma XII (ACCoRd)RecruitingNCT03562169Phase 3
• Impacts on Health Outcomes and Resources Utilization of Hospital-at-home for Elderly Patients With Multiple MyelomaRecruitingNCT03490084
• Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic CancerRecruitingNCT03412877Phase 2
• Long-term Follow-up Study of Patients Receiving CAR-T CellsRecruitingNCT03375619
• Myeloablative Allo HSCT With Related or Unrelated Donor for Heme DisordersRecruitingNCT03314974Phase 2
• Myeloma Registry Platform (MYRIAM)RecruitingNCT03308474
• Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)RecruitingNCT03297606Phase 2
• Multi-CAR T Cell Therapy in the Treatment of Multiple MyelomaNot yet recruitingNCT03271632Phase 1/2
• Study of T Cells Targeting CD138/BCMA/CD19/More Antigens (CART-138/BCMA/19/More) for Chemotherapy Refractory and Relapsed Multiple MyelomaRecruitingNCT03196414Phase 1/2
• Assessment of Allogeneic Hematopoietic Cell Transplantation in Medicare Beneficiaries With Multiple MyelomaRecruitingNCT03127761
• Expanded Access to VenetoclaxAvailableNCT03123029
• A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) PatientsRecruitingNCT03110822Phase 1
• A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or LymphomaRecruitingNCT03017820Phase 1
• Umbilical Cord Blood Transplantation From Unrelated DonorsRecruitingNCT03016806
• Institut Paoli Calmettes Multiple Myeloma DatabaseRecruitingNCT02869555
• TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage CancerRecruitingNCT02693535Phase 2
• Biospecimen Procurement for Center for Immuno-Oncology Immunotherapy ProtocolsRecruitingNCT02682667
• Gene Therapy Follow-up Protocol for People Previously Enrolled in CAR-T Cell StudiesEnrolling by invitationNCT02473757
• Selinexor and Backbone Treatments of Multiple Myeloma PatientsRecruitingNCT02343042Phase 1/2
• Cancer Experience Registry (CER) for Cancer Patients and CaregiversRecruitingNCT02333604
• Prospective Cohort With Hemopathy in Languedoc-RoussillonRecruitingNCT02134574
• Integrated Cancer Repository for Cancer ResearchRecruitingNCT02012699
• The Prospective Collection, Storage and Reporting of Data on Patients Undergoing Hematopoietic Stem Cell Transplantation Utilizing a Standard Preparative RegimenRecruitingNCT01890486
• Tissue Collection for Studies of Lymph CancerRecruitingNCT01676805
• Ohio State University Multiple Myeloma and Amyloidosis Data Registry and Sample ResourceRecruitingNCT01408225
• Technology Platform and System Construction of Clinical Evaluation Studies on New Drugs of Hematological MalignancyAvailableNCT01250808
• Registry of Older Patients With CancerRecruitingNCT01137825
• Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic CancerRecruitingNCT01137643
• Collection of Tissue Samples for Cancer ResearchRecruitingNCT00900198
• Collection of Samples and Clinical Data From Patients With Amyloid DiseasesRecruitingNCT00898235
• Total Marrow Irradiation & Autologous Stem Cell Transplantation for Relapsed or Refractory MyelomaRecruitingNCT00800059Phase 1/2
• Family Study of Lymphoproliferative DisordersRecruitingNCT00626496
• Ascertainment of Families for Genetic Studies of Familial Lymphoproliferative DisordersRecruitingNCT00582621
• Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Isatuximab in Participants With RRMMActive, not recruitingNCT07217184Phase 1/2Results posted
• Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Feladilimab (GSK3359609) in Participants With RRMMActive, not recruitingNCT07217119Phase 1/2Results posted
• Sub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Nirogacestat, Pomalidomide, and Dexamethasone in Participants With RRMMActive, not recruitingNCT07150104Phase 1/2Results posted
• Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat, Lenalidomide, and Dexamethasone in Participants With RRMMActive, not recruitingNCT07150091Phase 1/2Results posted
• Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat in Participants With RRMMActive, not recruitingNCT07084896Phase 1/2Results posted
• All Japanese Population: Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple MyelomaActive, not recruitingNCT06956170Phase 3Results posted
• Japan Expansion Cohort: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple MyelomaActive, not recruitingNCT06868667Phase 3Results posted
• China Subpopulation: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple MyelomaActive, not recruitingNCT06868654Phase 3Results posted
• Sub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Dostarlimab (GSK4057190) in Participants With RRMMTerminatedNCT06655818Phase 1/2Results posted
• A Study to Compare the Effects of Elranatamab (PF 06863135) Versus Standard of Care (SOC) in Patients With Multiple Myeloma (MM) in Germany and USCompletedNCT06504524Results posted
• Testing Ipatasertib as Potentially Targeted Treatment in Cancers With AKT Genetic Changes (MATCH - Subprotocol Z1K)Active, not recruitingNCT06400251Phase 2Results posted
• Testing Copanlisib as Potentially Targeting Treatment in Cancers With PTEN Expression (MATCH - Subprotocol Z1H)Active, not recruitingNCT06400238Phase 2Results posted
• Testing LOXO-101 as Potentially Targeted Treatment in Cancers With NTRK Genetic Changes (MATCH - Subprotocol Z1E)Active, not recruitingNCT06390852Phase 2Results posted
• Testing Sunitinib as Potentially Targeted Treatment in Cancers With cKIT Genetic Changes (MATCH - Subprotocol V)Active, not recruitingNCT06390826Phase 2Results posted
• Testing Afatinib as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH - Subprotocol A)Active, not recruitingNCT06385483Phase 2Results posted
• Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Exon 14 Deletion Genetic Changes (MATCH - Subprotocol C2)Active, not recruitingNCT06360575Phase 2Results posted
• Testing GDC-0449 (Vismodegib) as Potentially Targeted Treatment in Cancers With Smoothened or Patched 1 Mutant Tumors (MATCH - Subprotocol T)Active, not recruitingNCT06357988Phase 2Results posted
• Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Genetic Changes (MATCH - Subprotocol C1)Active, not recruitingNCT06357975Phase 2Results posted
• Testing JNJ-42756493 (Erdafitinib) as Potentially Targeting Treatment in Cancers With FGFR Amplifications (MATCH-Subprotocol K1)Active, not recruitingNCT06308822Phase 2Results posted
• Testing AZD9291 as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH-Subprotocol E)Active, not recruitingNCT06303167Phase 2Results posted
• Platform Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With aOX40 (GSK3174998) in Participants With RRMMTerminatedNCT06160609Phase 1/2Results posted
• Evaluation of a Pain Management Intervention Preparatory to a Future Pragmatic Trial, ASCENT StudyCompletedNCT06063603Not applicableResults posted
• A Study Evaluating Safety, Tolerability, and Clinical Activity of Forimtamig-Based Treatment Combinations in Participants With Relapsed or Refractory Multiple MyelomaTerminatedNCT06055075Phase 1/2Results posted
• Real-World Analysis of Belantamab Mafodotin Care Patterns in Patients With Relapsed and/or Refractory Multiple MyelomaCompletedNCT05986682Results posted
• Scalp Cooling to Prevent Hair Loss in Patients Undergoing Stem Cell Transplantation for Multiple MyelomaCompletedNCT05961215Not applicableResults posted
• A Study to Learn About the Effectiveness of the Medicine Called Elranatamab in People With Relapsed Refractory Multiple MyelomaCompletedNCT05932290Results posted
• Isa-Pom-Dex in Elderly/Frail Subjects With RRMMActive, not recruitingNCT05911321Phase 2Results posted
• A Survey on NINLARO Risk Management Plan (RMP) Material Utilization Among Pharmacists in JapanCompletedNCT05882279Results posted
• COVID19 OutcomeS in Myeloma and the Impact of VaCcinesCompletedNCT05831787Results posted
• Fluoroquinolone Resistance Prevalence StudyTerminatedNCT05824689Results posted
• Health Through Activity: A Pilot Study of a Rehabilitation Intervention for People Living With Multiple MyelomaCompletedNCT05700747Not applicableResults posted
• ImmunoCARE: Rapid, Accurate COVID Testing to Reduce Hospitalization of Immunocompromised IndividualsTerminatedNCT05655546Not applicableResults posted
• A Study of Modakafusp Alfa Together With Daratumumab Adults With Relapsed or Refractory Multiple MyelomaTerminatedNCT05590377Phase 1/2Results posted
• PROFAST Intervention in Precursor Multiple MyelomaCompletedNCT05565638Not applicableResults posted
• A Study to Learn About the Medicine (Called Elranatamab) in People With Relapsed Refractory Multiple MyelomaCompletedNCT05565391Results posted
• A Study of Modakafusp Alfa in Adult Participants With Multiple MyelomaTerminatedNCT05556616Phase 1Results posted
• Home Based Daratumumab Administration for Patients With Multiple MyelomaCompletedNCT05511428Phase 4Results posted
• Testing Copanlisib as a Potential Targeted Treatment in Cancers With PIK3CA Mutations (MATCH-Subprotocol Z1F)Active, not recruitingNCT05490771Phase 2Results posted
• A Study of JNJ-68284528 Out-of-Specification (OOS) for Commercial Release in Participants With Multiple MyelomaCompletedNCT05347485Phase 2Results posted
• Immunomodulatory Drugs (Lenalidomide With or Without Pomalidomide) in Combination With a Corticosteroid Drug (Dexamethasone) for the Treatment of Multiple MyelomaTerminatedNCT05288062Phase 2Results posted
• Chaplain-Delivered Compassion Meditation to Improve Quality of Life in Patients Receiving a Stem Cell TransplantCompletedNCT05274763Not applicableResults posted
• A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma.CompletedNCT05228470Phase 2Results posted
• Pembrolizumab for the Treatment of Relapsed or Refractory Multiple Myeloma After Anti-BCMA CAR-T TherapiesTerminatedNCT05191472Phase 2Results posted
• A Study of the Safety, Tolerability and Effectiveness of EZM0414 (IPN60210) Investigative Product in Participants With Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B Cell LymphomaTerminatedNCT05121103Phase 1Results posted
• Maintenance Belantamab Mafodotin (Blenrep®) After B-cell Maturation Antigen-Directed Chimeric Antigen Receptor T-cell Therapy in Patients With Relapsed and/or Refractory Multiple MyelomaTerminatedNCT05117008Phase 2Results posted
• MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple MyelomaTerminatedNCT05090566Phase 2Results posted
• Study to Investigate Alternative Dosing Regimens of Belantamab Mafodotin in Participants With Relapsed or Refractory Multiple MyelomaCompletedNCT05064358Phase 2Results posted
• Upfront Chimeric Antigen Receptor T-Cell to Upgrade Response in Multiple MyelomaCompletedNCT05032820Phase 2Results posted

← Multiple Myeloma overview